These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The use of high-dose megestrol acetate in the treatment of ovarian adenocarcinoma.
    Author: Geisler HE.
    Journal: Semin Oncol; 1985 Mar; 12(1 Suppl 1):20-2. PubMed ID: 3975647.
    Abstract:
    This study investigated the use of a progestin, megestrol acetate, in high doses for 34 patients with ovarian adenocarcinoma and related gynecologic tumors. Megestrol acetate was administered in doses of 800 mg/d orally for one month, followed by 400 mg/d until the first signs of progression of disease. Of 23 evaluable patients, seven patients showed a complete response and four patients a partial response. Ten of the responders had ovarian adenocarcinoma, and one, who is alive and free of disease 96 months after treatment, had a mesothelioma. The remaining six patients achieving complete response survived from 5 to 36 months, and those achieving partial response survived from 4 to 10 months. In contrast, studies of progestins administered in conventional doses to ovarian carcinoma patients have yielded minimal response at best. Our results confirm the benefits of high-dose progestins for ovarian carcinomas and related gynecologic tumors and warrant further investigation of hormonal therapy for this patient group.
    [Abstract] [Full Text] [Related] [New Search]